Utility of serum eosinophil-derived neurotoxin (EDN) measurement by ELISA in young children with asthma

Abstract

Background

This study was done to compare the efficacy of a recently developed eosinophil-derived neurotoxin (EDN) ELISA kit (“BioTracer™ K® EDN ELISA Kit”) to a commercially available EDN ELISA kit (“MBL EDN ELISA Kit”) and demonstrate the usefulness of serum EDN measurement in young asthmatic children.

Methods

Forty-eight children with physician-diagnosed asthma (Asthma group) and 31 age-matched normal controls (Control group) were recruited from the Asthma and Allergy Center at Inje University Sanggye Paik Hospital, Seoul, Korea from January 2010 to September of 2012. EDN levels in each serum specimen were measured 2 times using the: 1) BioTracer™ K® EDN ELISA Kit and 2) MBL EDN ELISA Kit at the Inje University Sanggye Paik Hospital laboratory. EDN level measurements in each serum specimen were compared.

Results

EDN measurements from the BioTracer™ K® EDN ELISA Kit correlated well with those from the MBL EDN ELISA Kit: r = 0.9472 at the Inje University Sanggye Paik Hospital laboratory. These r values were considered both clinically relevant (i.e., r > 0.85) and statistically significant (p < 0.0001). EDN measurements from both kits positively correlated with asthma symptom severity (p < 0.0001). No serious adverse events occurred during the study.

Conclusions

The BioTracer™ K® EDN ELISA Kit was accurate and useful in measuring EDN levels in young asthma patient serum. Because of our kit's distinct advantages and utility, we suggest this kit can be used for the timely diagnosis, treatment, and monitoring of asthma in asthma patients of all ages, especially those too young to perform pulmonary function tests.

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Top story: Allergen immunotherapy: Challenges for the prevention of asthma https://t.co/1uQLhmOQmu, see more https://t.co/CpGiFuOOYd
1hreplyretweetfavorite
Interasma RT @ARIAGuideline: Integrated care pathways for predictive, preventive and personalized medicine across the life cycle. https://t.co/UPig39
13hreplyretweetfavorite
Interasma RT @Aller_MD: Preventive treatment for peanut #allergies succeeds in study https://t.co/XFciizB0Tg
13hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Allergen immunotherapy: Challenges for the prevention of asthma https://t.co/kkDKTTDNRp, see more https://t.co/jgC
13hreplyretweetfavorite
Interasma RT @Aller_MD: Early childhood immune signature predicts risk of developing #asthma later on https://t.co/JyM2Fovjnn
13hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma